9/17/2013 9:23:54 AM
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today it
received clinical milestone payments from Janssen Biotech, Inc. ("Janssen")
following the initiation of two clinical trials. One trial initiated in
asthmatic patients is studying the HuCAL antibody CNTO 3157 and a second trial
initiated in patients with active rheumatoid arthritis is studying the HuCAL
antibody CNTO 6785. Further financial details were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by